三阴性乳腺癌免疫治疗耐药机制的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.011

Abstract

Abstract: Triple-negative breast cancer (TNBC) can benefit from immunotherapy because of its higher tumor mutational burden (TMB) and tumor-infiltrating lymphocytes. Although immunotherapy has made breakthroughs as an important treatment strategy for TNBC, recent clinical data suggest that a proportion of patients exhibit resistance to immunotherapy, or those who are effective in treatment experience further recurrence or progression. The main reason for these poor prognosis is complex internal or external immune escape mechanisms, which may be caused by abnormal antigen presentation, immunosuppressive tumor microenvironment, interactions with other immune checkpoints, and abnormal activation of tumor cell signaling. However, the research on the resistance mechanism of TNBC immunotherapy is still incomplete. This article will provide a review of the challenges faced by immunotherapy and the potential mechanisms of TNBC develops resistance to immunotherapy.

Key words: Triple negative breast cancer, Immunotherapy, Immune resistance

CLC Number:

R737.9

CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer[J]. Journal of Practical Oncology, 2023, 37(5): 449-453.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I5/449

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Andrews LP,Yano H,Vignali DA.Inhibitory receptors and ligands beyond PD-1,PD-L1 and CTLA-4:Breakthroughs or backups[J].Nat Immunol,2019,20(11):1425-1434.
3 Garrido MA,Rodriguez T,Zinchenko S,et al.HLA class I alterations in breast car-cinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15[J].Immunogenetics,2018;70(10):647-659.
4 Lee JV,Housley F,Yau C,et al.Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer[J].Nat Commun,2022,13(1):3671.
5 Nomura T,Huang WC,Zhau HE,et al.β2-Microglobulin-mediated signaling as a target for cancer therapy[J].Anticancer Agents Med Chem,2014,14(3):343-352.
6 Song X,Zhou Z,Li H,et al.Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers[J].Cancer Discov,2020,10(12):1872-1893.
7 Huang Y,Zhang HL,Li ZL,et al.FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer[J].Nat Commun,2021,12(1):2672.
8 Li XJ,Du H,Zhan SH,et al.The interaction between the soluble programmed death ligand-1(sPD-L1)and PD-1(+)regulator B cells mediates immunosuppression in triple-negative breast cancer[J].Front Immunol,2022,13:830606.
9 Castagnoli L,Cancila V,Cordoba-Romero SL,et al.WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer[J].Oncogene,2019,38(21):4047-4060.
10 Franklin DA,Sharick JT,Ericsson-Gonzalez PI,et al.MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC[J].JCI Insight,2020,5(15):e134290.
11 Franklin DA,James JL,Axelrod ML,et al.MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression[J].Cancer Drug Resist,2020,3(3):603-612.
12 Peng WY,Chen JQ,Liu CW,et al.Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J].Cancer Discov,2016,6(2):202-216.
13 Wu BB,Song M,Dong Q,et al.UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer[J].Research Paper,2022,12(11):5086-5102.
14 Zhang M,Wang N,Song P,et al.LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1[J].Cell Proliferation,2020,53(9):12855.
15 Sami E,Paul BT,Koziol JA,et al.The immunosuppressive microenvironment in BRCA1-IRIS-Overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages[J].Cancer Res,2020,80(5):1102-1117.
16 Roux C,Jafari SM,Shinde R,et al.Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1[J].Proc Natl Acad Sci U S A,2019,116(10):4326-4335.
17 Ji P,Gong Y,Jin ML,et al.In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer[J].Sci Adv,2022,8(26):eabl8247.
18 Liu L,Cheng XF,Yang H,et al.BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion[J].Mol Cancer,2022,21(1):59.
19 Knutson KL,Disis ML.Tumor antigen-specific T helper cells in cancer immunity and immunotherapy[J].Cancer Immunol Immunother,2005,54(8):721-728.
20 Guery L,Hugues S.Th17 cell plasticity and functions in cancer immunity[J].Biomed Res Int,2015,2015:314620.
21 Han GC,Yang GL,Hao DP,et al.9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy[J].Nat Commun,2021,12(1):5606.
22 Ciriello G,Gatza ML,Beck AH,et al.Comprehensive molecular portraits of invasive lobular breast cancer[J].Cell,2015,163(2):506-519.
23 Yu B,Luo,F,Sun B,et al.KAT6A Acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment,metastasis,and immunotherapy in Triple-Negative breast cancer[J].Adv Sci(Weinh),2022,9(3):2105793.
24 Patel SA,Meyer JR,Greco SJ,et al.Mesenchymal stem cells protect breast cancer cells through regulatory T cells:role of mesenchymal stem cell-derived TGF-beta[J].J Immunol,2010,184(10):5885-5894.
25 Costa A,Kieffer Y,Scholer-Dahirel A,et al.Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J].Cancer Cell,2018,33(3):463-479.
26 Lu HQ,Samanta D,Xiang LS,et al.Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype[J].Proc Natl Acad Sci U S A,2015,112(33):4600-4609.
27 Bai XP,Ni J,Beretov J,et al.Cancer stem cell in breast cancer therapeutic resistance[J].Cancer Treat Rev,2018,69:152-163.
28 Bagati A,Kumar S,Jiang P,et al.Integrin αvβ6-TGFβ-SOX4 pathway drives immune evasion in triple-negative breast cancer[J].Cancer Cell,2021,39(1):54-67.
29 Cheng SW,Chen PC,Lin MH,et al.GBP5 repression suppresses the metastatic potential and PD-L1 expression in triple-negative breast cancer[J].Biomedicines,2021,9(4):371.
30 Li W,Tanikawa T,Kryczek I,et al.Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer[J].Cell Metab,2018,28(1):87-103.
31 Lim S,Li CW,Xia WY,et al.EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape[J].Cancer Res,2016,76(5):1284-1296.
32 Chaturvedi P,Gilkes DM,Takano N,et al.Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment[J].Proc Natl Acad Sci U S A,2014,111(20):2120-2129.
33 Ma SJ,Zhao Y,Lee WC,et al.Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy[J].Nat Commun,2022,13(1):4118.

[1]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[2]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[3]	LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(4): 372-376.
[4]	LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma [J]. Journal of Practical Oncology, 2023, 37(2): 144-148.
[5]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[6]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[7]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[8]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[9]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[10]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[11]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[12]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[13]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[14]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[15]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.

Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments